^
Association details:
| Biomarker: | HOXA9 overexpression + MEIS1 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | INT-1B3 (CD73 inhibitor, CD39 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA
Published date:
05/11/2023
Excerpt:
We took advantage of a primary murine AML transplantation model based on the combined overexpression of Hoxa9 and Meis1 (H9M)...To evaluate the effect of INT-1B3 on leukemogenesis in vivo, we engrafted H9M cells in a murine host with an intact immune system, allowing INT-1B3 to exert its immunomodulatory effects. Biweekly i.v. treatments of INT-1B3 after H9M cell transplantation prevented AML formation, highlighting the potent anti-leukemic activity of this miRNA based therapeutic...
